Amanta Healthcare Ltd

Amanta Healthcare Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut for insiders, connected persons, designated persons, and their immediate relatives from July 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. This measure is standard practice to prevent potential insider trading during sensitive financial reporting periods.

Amanta Healthcare Ltd has received a disclosure under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The disclosure, submitted in Form 'C', pertains to an open-market purchase of equity shares by Shri Bhavesh Girishbhai Patel, one of the company's promoters. The company has taken this information on record and acknowledged its receipt. This filing is a routine compliance requirement under insider trading regulations, informing the exchange about a promoter's transaction.

Amanta Healthcare Ltd has filed an intimation under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015. Promoter Shri Bhavesh Girishbhai Patel has disclosed an open-market purchase of equity shares on June 17, 2026. The filing includes Form 'C' detailing the transaction, which is a continual disclosure requirement for promoters regarding their trading activities in the company's securities.

Amanta Healthcare Ltd has filed a disclosure under SEBI's Insider Trading Regulations. Shri Kirit Ambalal Desai, a member of the promoter group, has reported an open-market sale of 11,33,079 equity shares. The transaction occurred on June 17, 2026, with a reported value of ₹7,45,28,528. This disclosure is a routine filing as per regulatory requirements concerning insider trading.

Amanta Healthcare Ltd has commissioned a 10.8 MWp solar power plant at Village Baroda, Taluka Matar, District Kheda. The plant will generate electricity for captive consumption, reducing operational costs and enhancing sustainability. Generation of units from the plant commenced on May 30, 2026, after receiving all necessary approvals.

Amanta Healthcare Ltd. reports no deviation or variation in the utilization of funds raised through its IPO for the quarter ended December 31, 2025. This is in compliance with Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Audit Committee has reviewed the statement, and the company confirms adherence to the prescribed format. The IPO raised ₹126 crore, and CRISIL Ratings Limited was the monitoring agency.

Amanta Healthcare Ltd. reports no deviation or variation in the utilization of funds raised through its IPO for the quarter ended March 31, 2026. This is in compliance with Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report, reviewed by the Audit Committee, confirms adherence to the originally stated objectives for the IPO proceeds. Issue expenses were higher than estimated in the prospectus by ₹358.38 lakhs and adjusted with general corporate purposes cost.

Amanta Healthcare Ltd's board approved a revision in the remuneration of Shri Bhavesh Patel, Chairman & Managing Director, subject to shareholder approval at the upcoming Annual General Meeting. The revised remuneration is proposed at ₹13,29,000 per month, effective from April 1, 2026, until further reappointment. This is an increase from the existing remuneration of ₹10,00,000 per month. The decision was made during the board meeting held on May 19, 2026.

The Board of Directors of Amanta Healthcare Limited, in its meeting on May 19, 2026, approved the appointment and re-appointment of various auditors. M/s. Kashyap R. Mehta & Partners was appointed as Secretarial Auditor for a 5-year term, subject to shareholder approval. M/s. Parikh Shah & Associates was re-appointed as Internal Auditor, and M/s Y S THAKAR & Co. was re-appointed as Cost Auditor, both for the financial year 2026-27.

Amanta Healthcare Limited announced its Q4 and FY26 results, reporting a 42% YoY increase in profit after tax (PAT) for FY26, reaching ₹15 crore. Revenue for FY26 stood at ₹288 crore, a 5% YoY increase. The company's Q4FY26 revenue was ₹77 crore, up 7% YoY, with a PAT of ₹5.5 crore, a 28% YoY increase. The company is focused on scaling high-margin SteriPort and SVP capacities and expanding its market presence.